文献速递真菌感染

肺表面活性物质与用于治疗和预防侵袭性曲霉病的抗真菌药物的体外相互作用

Interaction in vitro of pulmonary surfactant with antifungal agents used for treatment and prevention of invasive aspergillosis.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

采用EUCAST方法,在24株不同曲霉属临床分离株中测试两性霉素B制剂、具抗霉菌活性的三唑类和棘白菌素类,加与不加猪肺表面活性物质(Curosurf®)。加入终浓度10%表面活性物质后,两性霉素B的24小时几何平均MIC显著降低,三唑类48小时几何平均MIC和棘白菌素类24及48小时几何平均MEC显著升高,但作者认为影响轻微且可能无关。

要点

  • 加入10%猪肺表面活性物质后,两性霉素B制剂24小时几何平均MIC显著降低(0.765 vs 0.552 mg/L;P < 0.05)。
  • 加入10%表面活性物质后,具抗霉菌活性的三唑类48小时几何平均MIC显著升高(0.625 vs 0.898 mg/L;P < 0.05)。
  • 加入10%表面活性物质后,棘白菌素类24小时(0.409 vs 0.6532 mg/L;P < 0.01)和48小时(0.527 vs 0.9378 mg/L;P < 0.01)几何平均MEC显著升高。

核心结论

  • 采用EUCAST方法,加入终浓度不超过10%的猪表面活性物质对用于预防和治疗侵袭性肺曲霉病的抗真菌药物体外活性影响轻微,推测无临床相关性。

研究设计与样本

  • 体外研究,针对24株不同曲霉属临床分离株,测试两性霉素B制剂、具抗霉菌活性的三唑类和棘白菌素类,加与不加商品化猪表面活性物质(Curosurf®;Poractant alfa)。

主要发现

  • 两性霉素B制剂加入终浓度10%表面活性物质后,所有测试曲霉分离株24小时几何平均MIC显著降低(0.765 vs 0.552 mg/L;P < 0.05)。
  • 具抗霉菌活性的三唑类加入10%表面活性物质后,48小时几何平均MIC显著升高(0.625 vs 0.898 mg/L;P < 0.05)。
  • 棘白菌素类加入10%表面活性物质后,24小时(0.409 vs 0.6532 mg/L;P < 0.01)和48小时(0.527 vs 0.9378 mg/L;P < 0.01)几何平均MEC均显著升高。
  • 三类抗真菌药物各自成员之间及所测不同曲霉属之间无有意义的差异。

关键数值与推荐

  • 数据以MIC或最低有效浓度(MEC)范围、抑制90%分离株的MIC或MEC值(MIC90或MEC90)及几何平均MIC或MEC值呈现。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimizing antifungal therapy is important to improve outcomes in severely immunocompromised patients. OBJECTIVES: We analysed the in vitro interaction between pulmonary surfactant and antifungal agents used for management of invasive pulmonary aspergillosis. METHODS: Amphotericin B formulations, mould-active triazoles and echinocandins were tested in vitro against 24 clinical isolates of different Aspergillus spp. with and without the addition of a commercial porcine surfactant (Curosurf®; Poractant alfa, Nycomed, Austria). The data are presented as MIC or minimum effective concentration (MEC) ranges, as MIC or MEC values that inhibited 90% of the isolates (MIC90 or MEC90) and as geometric mean (GM) MIC or MEC values. RESULTS: For amphotericin B products, addition of surfactant to a final concentration of 10% led to a statistically significant reduction of the GM MIC for all Aspergillus isolates tested after 24 h (0.765 versus 0.552 mg/L; P < 0.05). For the mould-active triazoles, addition of 10% surfactant resulted in a significantly higher GM MIC at 48 h (0.625 versus 0.898 mg/L; P < 0.05). For the echinocandins, the addition of 10% surfactant led to a significantly higher GM MEC after both 24 h (0.409 versus 0.6532 mg/L; P < 0.01) and 48 h (0.527 versus 0.9378 mg/L; P < 0.01). There were no meaningful differences between individual members of the three existing classes of antifungal agents or between the different Aspergillus spp. tested. CONCLUSIONS: Using EUCAST methodology, addition of porcine surfactant up to a concentration of 10% had a minor, and presumably non-relevant, impact on the in vitro activity of antifungal agents used in prophylaxis and treatment of invasive pulmonary aspergillosis.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Rauwolf KK, Hoertnagl C, Lass-Floerl C, et al. Interaction in vitro of pulmonary surfactant with antifungal agents used for treatment and prevention of invasive aspergillosis. J Antimicrob Chemother. 2022. PMID: 34788449. doi:10.1093/jac/dkab422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。